-+ 0.00%
-+ 0.00%
-+ 0.00%

Replimune plans RP1 melanoma BLA resubmission after FDA talks

PUBT·05/29/2026 12:05:22
Listen to the news
Replimune plans RP1 melanoma BLA resubmission after FDA talks
  • Replimune plans to resubmit its RP1 biologics license application for advanced melanoma in the coming days following FDA discussions.
  • The FDA signaled it will treat the resubmission as urgent and prioritize the review once received.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Replimune Group Inc. published the original content used to generate this news brief on May 29, 2026, and is solely responsible for the information contained therein.